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Previewsendogenous in vivo counterparts. This
point might be relevant if iNCCs will be
used to study mechanisms of fate
specification and cellular differentiation
or to pursue functional cell replacement
strategies in the future.
In any case, the iNCCs generated by
Kim and coauthors constitute a very
valuable platform for the detection of
new mechanisms underlying NC-related
diseases. Indeed, in this study the authors
not only showed that FD-patient iNCCs
displayed low levels of the IKBAKP
transcript most likely due to alternative
splicing, but they also identified novel
splicing variants in two core NC transcrip-
tion factors (Figure 1). It will be interesting
to use iNCCs in large-scale drug screen-
ings to identify new molecules capable
of reversing the phenotype of thisand other diseases. Thus, iNCCs hold
great potential for cell-based therapies.
To realize this potential, however, the
genomic integration of retrovirally trans-
duced Sox10 must be circumvented, for
instance with chemical reprogramming.
Additionally, it is crucial that the function-
ality of newly generated cell types will be
validated in in vivo disease models.REFERENCES
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Hematopoietic stem cells (HSCs) functionally decline and are prone to lineage bias andmyeloidmalignancies
upon aging. Two recent studies (Beerman et al., 2014; Flach et al., 2014) investigate the underlying mecha-
nisms associated with aged HSC phenotypes and highlight DNA damage, replication stress, and ribosomal
stress in the process.Aging is a complex phenomenon that
affects tissue homeostasis and is thought
to combine cell-intrinsic and -extrinsic
mechanisms (Oh et al., 2014). Old mice
develop an aged phenotype in the he-
matopoietic system that includes a re-
duced regenerative potential, a lymphoid
to myeloid lineage bias, and a tendency
of myeloid clones to expand toward
malignancies. There is a relative increase
of phenotypically defined HSCs in the
bone marrow from old mice; however,
these cells have less repopulating ability
than those from young mice in competi-
tive experiments, which reflects their
intrinsic functional decline together with
multiple epigenome and transcriptome
changes (Sun et al., 2014). HSC agingcoincides with the accumulation of unre-
solved DNA damage, which may not only
reflect but also participate in triggering
the cell-intrinsic aged phenotype. The
assumption of a driver role for DNA
damage accumulation is further sup-
ported by the aged phenotype observed
in mice with deficiencies in DNA repair
(Rossi et al., 2007). All together, the cir-
cumstances in which DNA damage
occurs in HSCs, the response at the
molecular and biochemical levels, and
the biological impact unresolved damage
has at the cell and tissue levels are
fundamental yet unanswered questions.
Such answers may reveal strategies for
modulating the mechanisms underlying
aging.Some important clues have been ad-
dressed in two recent papers, which both
began by studying the phosphorylated
form of the variant histone H2AX (gH2AX)
foci (using immunofluorescent detection)
and DNA breaks directly (using alkaline
comet assay) in highly purified HSCs
from young and old mice (Beerman et al.,
2014; Flach et al., 2014). It was previously
shown that gH2AX foci, which are indica-
tive of DNA damage, increase in number
over time. In both papers the accumula-
tion of gH2AX in old HSCswas confirmed,
but they were interpreted differently and
these differences paved the way to sub-
sequent experiments and conclusions.
The Rossi team focused on the discreet
increase of DNA breaks, which they5, October 2, 2014 ª2014 Elsevier Inc. 399
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Previewsdetected in old quiescent HSCs. By
analyzing the timing of the DNA damage
response and repair with the comet assay
and gene expression profiling of sorted
HSC and progenitor fractions (HSCs,
MPPs, GMPs, and CLPs) as well as HSC
fate in single-cell culture, the authors
found unexpectedly that the HSCs, which
are essentially quiescent, respond to and
repair DNA damage less efficiently than
the downstream progenitors, regardless
of age. This decrease was associated
with a broad attenuation of the DNA dam-
age response and repair pathways and
was dependent upon HSC quiescence.
Conversely, these systems were induced
in proliferating HSCs, particularly in fetal
liver cells that are highly proliferative.
These data put forth a model in which
old hematopoietic cells uniquely accumu-
late DNA damage in the quiescent stem
cell compartment, with this damage being
largely resolved at subsequent stages
upon cell cycle entry. Because many
HSCs remain quiescent for a very long
time, the continuing accumulation of
DNA damage in these cells may eventu-
ally lead to their impaired function in old
age.
The Passegue team focused on
analyzing what kind of damage, distinct
from DNA breaks, could be primarily
marked by the gH2AX foci in old HSCs.
Exploration of many checkpoint and
repair proteins revealed an excess of
ATR and single-stranded DNA binding
protein signaling in old HSCs, indicative
of a high level of replication stress with
impaired S phase progression in these
cells and subsequent acquisition of chro-
mosomal gaps or breaks in the progeny in
culture. Gene expression profiling was
performed and identified a selective
downregulation of all the Mcm genes in
old HSCs as a plausible origin of the repli-
cation stress, in line with a protective role
of the MCM complex (Ibarra et al., 2008).
This relationship was confirmed experi-
mentally by showing that depleting the
Mcm proteins impaired stem cell proper-
ties in vitro and in vivo. The next step,
considering that most HSCs are quies-
cent and do not replicate, was to investi-
gate which cell structures are marked by
gH2AX in noncycling HSCs. Interestingly,
the authors found that the gH2AX foci co-
localized with nucleolar markers. Nucleoli
are primarily sites of rRNA transcription400 Cell Stem Cell 15, October 2, 2014 ª201and ribosome biogenesis, while ribosome
stress is central in the pathogenesis of
some bone marrow deficiency diseases
(Narla and Ebert, 2010). Consistently,
rRNA transcripts and ribosome biogen-
esis were found decreased in quiescent
HSCs from old mice, and elegant experi-
ments showed that the nucleolar gH2AX
marks disappeared from old HSCs upon
cell cycle entry but were readily detected
months after transplantation, when
HSCs had re-entered quiescence. All
together, these data suggest that gH2AX
foci can mark replication stress or ribo-
somal stress at the rRNA genes sites
and that decreased ribosome biogenesis
is a hallmark of old quiescent HSCs.
These papers contribute to a better
knowledge of cell-intrinsic mechanisms
of the complex HSC aging phenotype.
While multiple cytoprotective properties
are active in HSCs to prevent cell
damage (i.e., low oxygen exposure in the
hematopoietic niche, detoxifying systems,
etc.), the study of Beerman et al. argues
against the usual view that these cells
are uniquely genoprotected during aging
by enhanced DNA repair systems ability.
Moreover, the study of Flach et al. con-
vincingly highlights the replication stress
and decreased ribosome biogenesis in
the biology of aged HSCs. These works
raise many questions, including questions
about the nature of the molecular signals
that regulate the damage response sys-
tems in the HSCs, and the downstream
mechanismsbywhich thedamageaccrual
may contribute to functional decline. More
generally, one can ask whether the accu-
mulation of various damage and DNA
mutations in the stem cell compartment
could be seen as playing a physiological
‘‘integrative’’ role in tuning homeostasis
over aging. It is noteworthy that the current
studies have been conducted in mouse
cells, so human HSCs will have to be
investigated, with their inherent practical
difficulties.
The results of these studies also have
implications for the cancer field regarding
cancer initiation and progression. Unre-
solvedormisrepairedDNAdamage favors
the accumulation of mutations. This accu-
mulation can start in utero and increases
over the life time, as was shown by exome
sequencing of healthy human hemato-
poietic progenitor cells (including those
from cord blood) and the deciphering of4 Elsevier Inc.the age-dependent mutational history
captured in leukemia cells (Alexandrov
et al., 2013; Welch et al., 2012). Although
the vast majority of the mutations in
HSCS are likely to be neutral (passenger),
the occurrence of driver mutations could
favor a progressive clonal dominance
over the surrounding aged (declining) cells
(Busque et al., 2012). It is also conceivable
that when a driver mutation occurs, the
quiescent state intrinsic to HSCs (or the
quiescence conferred by the mutation to
a more differentiated progenitor) might
be permissive, in relation to an attenuated
DNA damage and repair response, to
allow the cell to survive and additional mu-
tations to occur toward eventual expan-
sion of a successfully transformed clone.
This scenario would be consistent with
certain mutations that are observed in
myeloid malignancies that act as drivers
of oncogenesis, although they are appar-
ently ‘‘counterproductive’’whenobserved
in isolation.REFERENCES
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